Oslo, Norway, April 30, 2024 - Lytix Biopharma AS ("Lytix") (Euronext Growth
Oslo: LYTIX), a clinical stage immuno-oncology company, announces that it has
published its Annual Report for 2023, which was approved by the board of
directors on April 29, 2024.

"In 2023, our unique position in the immune-oncology field has been strengthened
with positive interim results from two phase II studies. Our oncolytic molecules
have the potential to solve one of the major challenges in current cancer
therapy: tumor heterogeneity", says Øystein Rekdal, CEO of Lytix Biopharma.

The Annual Report for 2023 is attached to this notice and is also available on
the company's website, www.lytixbiopharma.com, under Investors. 

For further information, please see the Company's website or contact CFO Gjest
Breistein. Please see below for contact details.

Gjest Breistein, CFO
E-mail: gjest.breistein@lytixbiopharma.com
Phone: +47 952 60 512

About Lytix
Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with
a highly novel technology based on world leading research in host-defense
peptide-derived molecules. Lytix Biopharma's lead product, LTX-315, is a
first-in-class oncolytic molecule representing a new principle to boost
anti-cancer immunity. Lytix Biopharma has a pipeline of molecules that can work
in many different cancer indications and treatment settings, both as mono- and
combination therapy.